Oral contraceptive use and breast cancer risk: Current status

Mayo Clinic Proceedings

Volumn 81, Issue 10, 2006, Pages 1287-1289

  Cerhan, James R ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ESTROGEN; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

BREAST CANCER; CANCER RISK; CEREBROVASCULAR ACCIDENT; EDITORIAL; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LIVER CANCER; MENOPAUSE; ORAL CONTRACEPTION; PREGNANCY; PREMENOPAUSE; RISK BENEFIT ANALYSIS; UTERINE CERVIX CANCER; VENOUS THROMBOEMBOLISM;

EID: 33749265296     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.10.1287     Document Type: Editorial

References (16)

1. Romieu I, Berlin JA, Colditz G. Oral contraceptives and breast cancer: review and meta-analysis. Cancer. 1990;66:2253-2263.
2. Thomas DB. Oral contraceptives and breast cancer: review of the epidemiologic literature. Contraception. 1991;43:597-642.
3. Delgado-Rodriguez M, Sillero-Arenas M, Rodriguez-Contreras R, Lopez Gigosos R, Galvez Vargas R. Oral contraceptives and breast cancer: a meta-analysis. Rev Epidemiol Sante Publique. 1991;39:165-181.
4. Rushton L, Jones DR. Oral contraceptive use and breast cancer risk: a meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use. Br J Obstet Gynaecol. 1992;99:239-246.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713-1727.
6. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 72: Hormonal Contraception and Post-menopausal Hormonal Therapy. Lyon, France: IARC; 1999.
7. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6:552-553.
8. Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol. 2001;44:62-72.
9. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, Md: National Cancer Institute; 2006.
10. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025-2032.
11. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev. 1995;4:567-571.
12. Russo J, Hu YF, Silva ID, Russo IH. Cancer risk related to mammary gland structure and development. Microsc Res Tech. 2001;52:204-223.
13. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81:1290-1302.
14. Pike MC, Henderson BE, Casagrande JT, Rosario I, Gray GE. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer. 1981;43:72-76.
15. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999;28:1-9.
16. Pymar HC, Creinin MD. The risks of oral contraceptive pills. Semin Reprod Med. 2001;19:305-312.